Drugs Made In America Acquisition Corp Units
DMAAU
9 hedge funds and large institutions have $10.2M invested in Drugs Made In America Acquisition Corp Units in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 7 closing their positions.
9.45% less ownership
Funds ownership: 14.28% → 4.83% (-9.4%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
40% less funds holding
Funds holding: 15 → 9 (-6)
70% less capital invested
Capital invested by funds: $33.4M → $10.2M (-$23.2M)
86% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 7
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$410K |
| 2 |
RCM
Robinson Capital Management
Grosse Pointe Farms,
Michigan
|
+$307K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Heights Capital Management
San Francisco,
California
|
-$6.58M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$6.14M |
| 3 |
WCMNY
Westchester Capital Management (New York)
Valhalla,
New York
|
-$5.06M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.39M |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
-$1.02M |
DMAAU Hedge Fund Activity: Q2 2025 in Review
9 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Units (DMAAU) for Q2 2025, worth a combined $10.2M — down 70% from $33.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DMAAU and 1 opened new positions — a net loss of 6 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Clear Street, adding an estimated $410K. The largest seller was Heights Capital Management, exiting entirely with an estimated $6.58M sold.
- 9 institutional investors held Drugs Made In America Acquisition Corp Units (DMAAU) as of Q2 2025, down from 15 in Q1 2025.
- Funds reported $10.2M of Drugs Made In America Acquisition Corp Units stock for Q2 2025, down 70% quarter-over-quarter.
- 1 fund opened new Drugs Made In America Acquisition Corp Units positions in Q2 2025 and 7 closed out, a net change of -6 holders.
- The largest Drugs Made In America Acquisition Corp Units buyer in Q2 2025 was Clear Street, an estimated $410K added.
- The largest Drugs Made In America Acquisition Corp Units seller in Q2 2025 was Heights Capital Management, an estimated $6.58M sold.
Based on aggregated 13F filings for Q2 2025.